^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    TrkA receptor antagonist

    Related drugs:
    Apply
    Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma (NCT03556228)
    Phase 1
    VM Oncology, LLC
    Recruiting
    Last update posted :
    05/31/2024
    Initiation :
    06/08/2018
    Primary completion :
    12/01/2025
    Completion :
    06/01/2026
    NTRK1
    |
    NTRK1 fusion • NTRK1 mutation • NTRK expression
    |
    VMD-928
    Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC (TRUST-II) (NCT04919811)
    Phase 2
    AnHeart Therapeutics Inc.
    Recruiting
    Last update posted :
    02/15/2024
    Initiation :
    09/01/2021
    Primary completion :
    06/01/2025
    Completion :
    06/01/2027
    ROS1
    |
    ROS1 fusion
    |
    Dovbleron (taletrectinib)
    A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene (TRUST) (NCT04395677)
    Phase 2
    AnHeart Therapeutics Inc.
    Active, not recruiting
    Last update posted :
    10/30/2023
    Initiation :
    07/07/2020
    Primary completion :
    12/30/2023
    Completion :
    12/31/2025
    ROS1
    |
    ROS1 fusion
    |
    Dovbleron (taletrectinib)
    Basket Study of AB-106 for the Treatment of Patients With Solid Tumors With NTRK Fusion Gene (NCT04617054)
    Phase 2
    AnHeart Therapeutics Inc.
    Recruiting
    Last update posted :
    06/21/2021
    Initiation :
    06/01/2021
    Primary completion :
    04/30/2024
    Completion :
    12/31/2026
    NTRK1 • NTRK3 • NTRK2
    |
    NTRK1 fusion • NTRK3 fusion • NTRK2 fusion
    |
    Dovbleron (taletrectinib)
    A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b (NCT02279433)
    Phase 1
    AnHeart Therapeutics Inc.
    Completed
    Last update posted :
    09/22/2020
    Initiation :
    09/01/2014
    Primary completion :
    03/01/2019
    Completion :
    03/01/2019
    KRAS • ROS1 • NTRK1 • NTRK3 • NTRK2 • RAS
    |
    RAS wild-type
    |
    Dovbleron (taletrectinib)